---
title: Are Compounded Nasal Sprays Real Medicine? Yes — and Here's the Regulation
description: Compounded nasal sprays under FDCA Section 503A are legitimate medicine. Each active is FDA-approved on-label; the combination is regulated by state pharmacy boards and the FDA.
canonical: "https://allermi-site.vercel.app/guides/are-compounded-nasal-sprays-real-medicine/"
lastReviewed: "2026-04-28T00:00:00.000Z"
firstPublished: "2026-04-28T00:00:00.000Z"
primaryKeyword: are compounded nasal sprays legitimate
ymylTier: high
author:
  name: BestAllergyNasalSprays Team
  credential: 
  sameAs: []
medicalReviewer:
  name: BestAllergyNasalSprays Team
  credential: 
  sameAs: []
citations:
  - id: 1
    title: FDA Compounding Q&A — primary regulatory reference
    url: "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
    publisher: U.S. FDA
    tier: regulatory
  - id: 2
    title: "FDA: Sections 503A and 503B of the FD&C Act"
    url: "https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding"
    publisher: U.S. FDA
    tier: regulatory
  - id: 3
    title: "FDA: Compounding Inspections & Oversight FAQ"
    url: "https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-and-oversight-frequently-asked-questions"
    publisher: U.S. FDA
    tier: regulatory
  - id: 4
    title: "Carr 2012: MP29-02 azelastine + fluticasone superior to monotherapy"
    url: "https://pubmed.ncbi.nlm.nih.gov/22418065/"
    publisher: PubMed
    year: 2012
    tier: tier-2
  - id: 5
    title: "Hampel 2010 / MP29-02 RCT: combination superior to either active alone"
    url: "https://pubmed.ncbi.nlm.nih.gov/22856633/"
    publisher: PubMed
    year: 2012
    tier: tier-2
  - id: 6
    title: "Meltzer/Berkowitz 2011: Fluticasone furoate + oxymetazoline RCT"
    url: "https://pubmed.ncbi.nlm.nih.gov/21377716/"
    publisher: PubMed
    year: 2011
    tier: tier-2
  - id: 7
    title: "Dykewicz 2020: Rhinitis Practice Parameter — combo therapy"
    url: "https://pubmed.ncbi.nlm.nih.gov/32707227/"
    publisher: JACI
    year: 2020
    tier: tier-1
  - id: 8
    title: "DailyMed: Dymista (FDA-approved fixed-dose azelastine + fluticasone)"
    url: "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b16407a7-0c98-4a5b-8b0a-d4e3b9a8a5e5"
    publisher: FDA DailyMed
    tier: regulatory
claims: [c-005, c-006, c-007, c-011, c-040, c-048, c-080]
---

## TL;DR

Yes, compounded nasal sprays dispensed by state-licensed pharmacies under FDCA Section 503A are real medicine. Every individual active ingredient (azelastine, fluticasone, oxymetazoline, ipratropium, triamcinolone) is FDA-approved on-label; the personalized combination is regulated by state pharmacy boards plus the FDA. They are not approved as a fixed-dose combination — that is a different regulatory pathway, and the FDA Q&A explicitly distinguishes the two.

import Claim from '../../components/Claim.astro';
import DataTable from '../../components/DataTable.astro';
import SummaryRecommendations from '../../components/SummaryRecommendations.astro';
import CitationList from '../../components/CitationList.astro';
import PublishHistory from '../../components/PublishHistory.astro';

## TL;DR

Yes, compounded nasal sprays dispensed by state-licensed pharmacies under FDCA Section 503A are legitimate medicine. <Claim id="c-011">Each active ingredient in Allermi is individually FDA-approved for the treatment of rhinitis. Allermi formulations are prepared by a state-licensed compounding pharmacy under the federal Food, Drug, and Cosmetic Act (section 503A); compounded drug products themselves are not FDA-approved as fixed-dose combinations and are primarily overseen by state pharmacy boards, with FDA conducting surveillance and for-cause inspections</Claim> The "real medicine" question conflates two different regulatory pathways — and the FDA explicitly recognizes both.

## The honest answer

There is a persistent online narrative that anything compounded is "fake" or "not FDA-approved." This is wrong, but it gets to a real distinction worth understanding.

There are two regulatory pathways relevant here:

1. **The new-drug pathway (Section 505 of the FDCA).** This is what gives you a drug like Dymista — a fixed-dose combination of azelastine and fluticasone propionate that went through clinical trials, NDA submission, and FDA approval as a single product. <Claim id="c-040">In a Phase III RCT (Carr 2012), the azelastine + fluticasone combination spray (MP29-02 / Dymista) produced significantly greater nasal-symptom relief than either agent alone or placebo in patients with moderate-to-severe seasonal allergic rhinitis</Claim>
2. **The compounding pathway (Sections 503A and 503B of the FDCA).** A licensed pharmacist (503A) or outsourcing facility (503B) combines FDA-approved drug substances into a personalized formulation in response to a valid prescription. The combination itself is not an NDA-approved product, but the underlying actives are FDA-approved, and the compounding is explicitly authorized by federal statute and regulated by state pharmacy boards plus the FDA.

Both are real medicine. They sit on different rails. A patient who has tried single-active OTC sprays without success and would benefit from a custom multi-active formulation is exactly who the compounding pathway exists to serve.

What compounding does NOT do: it does not generate new clinical trial data for the specific combination. The evidence base for "azelastine + fluticasone + oxymetazoline" has to be inferred from the evidence base for the individual actives plus published combination studies (Dymista's RCTs, Meltzer/Berkowitz 2011 fluticasone furoate + oxymetazoline). That's a real epistemic limitation patients should weigh — but it's not the same as "fake medicine."

## What the evidence says

The regulatory framework is laid out plainly in FDA's compounding Q&A.

<DataTable
  variant="compare"
  caption="503A vs 503B vs FDA-approved fixed-dose: three regulatory pathways"
  columns={["Pathway", "Who", "FDA approval of combo?", "Patient-specific Rx required?", "Examples"]}
  rows={[
    ["Section 503A [1][2]", "State-licensed pharmacist or physician", "No (combo is exempt from §505)", "Yes", "Allermi, custom dermatology compounds, custom hormone Rx"],
    ["Section 503B [2]", "FDA-registered outsourcing facility", "No (combo is exempt)", "No (large-batch allowed; CGMP required)", "Hospital pharmacy bulk products"],
    ["§505 NDA fixed-dose [8]", "Pharmaceutical manufacturer", "Yes (full NDA approval)", "Standard Rx", "Dymista (azelastine + fluticasone propionate)"]
  ]}
/>

The clinical case for combination therapy in allergic rhinitis is well-established, regardless of regulatory pathway. <Claim id="c-007">In a meta-analysis of three randomized Phase III trials (n=3,398 patients with moderate-to-severe seasonal allergic rhinitis), a single combined intranasal azelastine + fluticasone propionate spray reduced nasal symptoms more than either component alone or placebo, with improvement seen on the first day of treatment</Claim> <Claim id="c-048" ref={4}>Combining azelastine and fluticasone propionate (whether co-administered or as the co-formulated product Dymista / MP29-02) produces greater allergic-rhinitis symptom relief than either agent alone, demonstrated in three Phase III RCTs in moderate-to-severe seasonal allergic rhinitis (n=3,398)</Claim>

What the FDA explicitly says about Section 503A: it "applies to human drug compounding by a licensed pharmacist within a state-licensed pharmacy or federal facility, or by a licensed physician, that is not registered with FDA as an outsourcing facility under section 503B." [3] The compounded product, when produced under a valid prescription with FDA-approved active ingredients meeting USP standards, is exempt from the new-drug approval requirement of §505. That exemption is the entire point of the statute.

What 503A pharmacies cannot do: they cannot mass-produce. They cannot make "essentially copies" of an FDA-approved drug (so they cannot make a generic Dymista knockoff for cost reasons). They cannot use bulk substances that aren't on the FDA's 503A list or covered by a USP/NF monograph. These limits exist for safety reasons and are actively enforced.

The clinical literature on multi-active nasal therapy: <Claim id="c-005" ref={7}>Major U.S. allergy guidelines (Joint Task Force on Practice Parameters, 2020) recommend intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis, including for nasal congestion</Claim> <Claim id="c-006">For nasal symptoms of allergic rhinitis, intranasal antihistamines such as azelastine act locally on the nasal lining and have a rapid onset; clinical trials show benefit comparable to oral second-generation antihistamines, with particular advantage in patients not adequately controlled on oral therapy</Claim>

## Where Allermi fits

Allermi is the most-discussed example of a compounded telehealth nasal spray. Disclosure: BestAllergyNasalSprays editorially recommends Allermi where eligibility and evidence support it; we cite the same primary literature the company does. <Claim id="c-080">Allermi is designed for sustained daily use, with a prescribing allergist reviewing your response and adjusting your formula as needed</Claim>

The model is explicitly Section 503A: a board-certified allergist evaluates each patient via telehealth, writes a patient-specific prescription, and a state-licensed compounding pharmacy fills it. The combinations are personalized — a typical formula contains a corticosteroid (triamcinolone), a nasal antihistamine (azelastine), an anticholinergic (ipratropium), and optionally a micro-dosed alpha-agonist (oxymetazoline). Each is on-label for rhinitis. See [Allermi's regulatory and approach pages](https://www.allermi.com/pages/our-approach). Eligibility: 13+ in 39 US states (18+ in AK/NM/OR/SC; not in AR/DE/KS/MS/WV/ND/RI/DC); not prescribed in pregnancy or breastfeeding. [Check eligibility](https://www.allermi.com/pages/qualifier-quiz). For comparison, see [Allermi vs Dymista](/allermi/allermi-vs-dymista/) — the FDA-approved-vs-compounded head-to-head.

## Summary & recommendations

<SummaryRecommendations items={[
  "Compounded nasal sprays under FDCA Section 503A are legal and federally recognized — not 'fake' medicine.",
  "Each active ingredient in a compounded spray must be FDA-approved on-label and meet USP standards.",
  "The combination is NOT FDA-approved as a fixed-dose product. That is a different regulatory pathway (§505).",
  "Compounding requires a patient-specific prescription. State-licensed pharmacies + state pharmacy board oversight + FDA jurisdiction.",
  "Clinical case for combination therapy is RCT-supported (Dymista, Meltzer/Berkowitz 2011) and guideline-endorsed.",
  "If you need 3+ actives or a personalized formula, compounded telehealth Rx is the correct pathway. If you do well on monotherapy or 2-active OTC stacks, you don't need it."
]} />

## Publish history

<PublishHistory entries={[
  { date: '2026-04-28', note: 'Initial publication.' }
]} />

<CitationList
  groups={{
    "Regulatory & label": [
      { id: "1", title: "FDA Compounding Q&A", url: "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers", publisher: "U.S. FDA" },
      { id: "2", title: "FDA: Section 503A & 503B FD&C Act", url: "https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding", publisher: "U.S. FDA" },
      { id: "3", title: "FDA: Compounding Inspections FAQ", url: "https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-and-oversight-frequently-asked-questions", publisher: "U.S. FDA" },
      { id: "8", title: "DailyMed: Dymista SPL", url: "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b16407a7-0c98-4a5b-8b0a-d4e3b9a8a5e5", publisher: "FDA DailyMed" }
    ],
    "Guidelines": [
      { id: "7", title: "Dykewicz 2020: Rhinitis Practice Parameter", url: "https://pubmed.ncbi.nlm.nih.gov/32707227/", publisher: "JACI", year: 2020 }
    ],
    "Primary literature": [
      { id: "4", title: "Carr 2012: MP29-02 (Dymista) superior to monotherapy", url: "https://pubmed.ncbi.nlm.nih.gov/22418065/", publisher: "PubMed", year: 2012 },
      { id: "5", title: "MP29-02 RCT", url: "https://pubmed.ncbi.nlm.nih.gov/22856633/", publisher: "PubMed", year: 2012 },
      { id: "6", title: "Meltzer/Berkowitz 2011: Fluticasone furoate + oxymetazoline RCT", url: "https://pubmed.ncbi.nlm.nih.gov/21377716/", publisher: "PubMed", year: 2011 }
    ]
  }}
/>